English
This article is from Journal of Research in Medical Sciences : The Official Journal of Isfahan University of Medical Sciences , volume 17 . Abstract Background:: Hepatitis D virus (HDV) infection is characterized by rapidly progressive liver disease with adverse prognosis in most patients. Although interferon is the only approved anti-HDV therapy, evidence regarding the efficacy and safety of its various regimens is either old or scattered. Materials and Methods:: We searched systematically Medline, EMBASE, Scopus, the Cochrane Central Register of Controlled Trials, and ISI. The studies that evaluated treatment of chronic HDV infection with standard or pegylated interferon for at least 48 weeks were identified. Our inclusion criteria were positive anti-HDV antibody for 6 months and positive HDV-PCR at the start of study. We performed a meta-analysis for proportions using the arcsine transformation in random effects model. Sustained virological response (SVR) rate (negative Polymerase chain reaction (PCR) 6 months after cessation of therapy) was the end point of interest. Results:: Data were abstracted from 14 studies containing 227 chronic HDV-infected patients who received standar
Sign in with your free account to read, download EPUBs or listen.
Ebook · Standard and pegylated interferon therapy of HDV infection: A systematic review and meta- analysis. · Alavian, Seyed-Moayed, Tabatabaei, Seyed Vahid, Behnava, Bita, Rizzetto, Mario · Internet Archive